(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study ...
Getinge receives US FDA 510(k) clearance for three products, expanding the Servo ventilator platform
GOTEBORG, Sweden, April 22, 2021 /PRNewswire/ — Today, Getinge announces clearance from the US FDA of several new software options for the Servo-u and Servo-n ventilators. In addition to the latest ...
The Maquet SERVO-i ventilator battery module has been recalled due to the battery having a shorter run time than expected, according to the American Society of Anesthesiologists. The FDA assigned a ...
GETINGE, Sweden, April 10, 2019 /PRNewswire/ -- Getinge is today announcing clearance from the US Food & Drug Administration (FDA) for a new software version for the Servo-u® and Servo-n® mechanical ...
Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...
WAYNE, New Jersey, July 7, 2020 /PRNewswire/ -- US Food & Drug Administration (FDA) clears Servo-air® mechanical ventilator for use with adult and pediatric patients dependent on intensive care ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac ...
MONTREAL — The treatment of central sleep apnea in heart failure patients was in the spotlight here at CHEST 2015, as experts debated whether or not to completely reject the use of adaptive servo ...
The Maquet Getinge Group is recalling 90,000 defective batteries used with the SERVO-i ventilator system, the US Food and Drug Administration (FDA) announced May 7. The FDA said some battery modules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback